

***Remarks***

Reconsideration of this Application is respectfully requested.

Upon entry of the foregoing amendment, claims 1-14 are pending in the application, with claims 1, 10 and 11 being the independent claims. Claims 1, 10 and 11 are sought to be amended. New claims 12-14 are sought to be added. These changes are believed to introduce no new matter, and their entry is respectfully requested.

Based on the above amendment and the following remarks, Applicants respectfully request that the Examiner reconsider all outstanding objections and rejections and that they be withdrawn.

***Rejections under 35 U.S.C. § 112***

Claims 10 and 11 are rejected under 35 U.S.C. § 112, first paragraph, as being nonenabled. (Office Action, page 3, lines 6-12). Applicants respectfully traverse this rejection.

The Examiner objects to the terms "cancer" and "prevent" (Office Action, page 5). Applicants respectfully disagree with the Examiner's contentions.

However, solely in an effort to expedite the examination and allowance of the present application, the terms "cancer" and "prevent" have been deleted from the claims.

Withdrawal of the rejection is respectfully requested.

Claim 11 is rejected under 35 U.S.C. § 112, second paragraph as being indefinite. (Office Action, page 6, lines 9-11). Applicant respectfully traverses this rejection.

It is the Examiner's contention that the claim is indefinite as the limitation "in equimolar amounts" is not present in the claims. Applicant respectfully disagrees.

However, solely in an effort to expedite the examination and allowance of the present application, claim 11 has been amended to make clear that an equimolar amount of the underivitized NSAID is compared to the compounds of the invention.

Withdrawal of the rejection is respectfully requested.

***Rejections under 35 U.S.C. § 103***

Claims 1, 2 and 8-11 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Cramer *et al.* (WO 97/04808) (hereinafter "Cramer"). Applicant respectfully traverses this rejection.

It is the Examiner's opinion that the teachings of Cramer make obvious the compounds of the present invention in which naproxen is linked to glucosamine. (Office Action, page 8, lines 18-19). In particular, the Examiner reads Cramer as teaching the glucosamine salt of naproxen which, according to the Examiner, is glucosamine linked to naproxin. Applicants respectfully disagrees with the Examiner's contentions.

The term "link" is not intended to refer to salts. Instead, it is very clear from the context of the present invention that the NSAID and sugar molecular are covalently linked. However, solely in an effort to expedite the examination and allowance of the present application, claims 1, 10 and 11 have been amended to specifically require a covalent linkage.

The salt allegedly disclosed by Cramer does not make obvious the claimed compounds and uses thereof. Withdrawal of the rejection is respectfully requested.


***Conclusion***

All of the stated grounds of objection and rejection have been properly traversed, accommodated, or rendered moot. Applicants therefore respectfully request that the Examiner reconsider all presently outstanding objections and rejections and that they be withdrawn. Applicants believe that a full and complete reply has been made to the outstanding Office Action and, as such, the present application is in condition for allowance. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Prompt and favorable consideration of this Amendment and Reply is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond  
Attorney for Applicants  
Registration No. 32,893

Date: June 13, 2008

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

822763\_1.DOC